Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world's leading healthcare venture capital firms: OrbiMed, Fidelity Biosciences and HBM Partners. The Company's lead drug candidate is SYM-1219, a novel product containing secnidazole, which is a next-generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/06/15 | $41,000,000 | Series A |
HBM Partners OrbiMed Advisors | undisclosed |
